A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations

Clinical trial NCT01153984 · COMPLETED

Trial details

NCT number: NCT01153984
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma，Non-Small-Cell Lung

Start date: 2011-06-01
Primary completion: 2015-07-01
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.